Hostname: page-component-8448b6f56d-dnltx Total loading time: 0 Render date: 2024-04-23T15:45:34.527Z Has data issue: false hasContentIssue false
  • English
  • Français

Preclinical evidence for the role of serotonin receptor-subtypes in depression

Published online by Cambridge University Press:  18 September 2015

B. Olivier ,
J. Schipper ,
J.A.M. van der Heyden ,
A. van Hest ,
J. Mos  and
M.Th.M. Tulp
Get access Rights & Permissions [Opens in a new window]

Summary

Serotonin (5-HT) plays an important role in depression and specific 5-HT reuptake blockers appear to be clinically important antidepressants. It is unclear however, which serotonergic mechanism is involved in the antidepressant effect, certainly when regarding the existence of at least seven 5-HT receptor subtypes. By testing different 5-HT ligands in two animal models of depression (forced swimming and DRL72-S test) and comparison with data from literature, evidence is provided for potential antidepressant qualities of 5-HT1A receptor-agonists and 5-HT1C receptor-antagonists. Compounds binding to 5-HT1B, 5-HT2 and 5-HT3 receptors do not have an antidepressant profile. Results of clinical research support the predicted antidepressive effects of 5-HT1A receptor-agonists.

Keywords

serotonindepressionpreclinicalforced swimmingDRL72-SflesinoxanfluvoxamineSerotoninedepressiepreklinischzwemtestDRL72-Sflesinoxanfluvoxamine
Type
Research Article
Information
Acta Neuropsychiatrica , Volume 4 , Issue 2 , June 1992 , pp. 40 - 45
Copyright
Copyright © Scandinavian College of Neuropsychopharmacology 1992

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Literatuur

1.Meitzer, HY, Lowy, MT.The serotonin hypothesis of depression. In: Meitzer, HY, red. Psychopharmacology: The third generation of progress. Raven Press: New York, 1987: 513–26.Google Scholar
2.Coppen, A.The biochemistry of affective disorders. Br J Psychiat 1967; 113: 1237–64.CrossRefGoogle ScholarPubMed
3.Coppen, A, Prange, AJ Jr, Hill, C, Whybrow, PC, Noguera, R.Abnormalities of indoleamines in affective disorders. Arch gen Psychiat 1972; 26:474–8.CrossRefGoogle ScholarPubMed
4.Lapin, IP, Oxenburg, GF.Intensification of the central serotonergic processes as a possible determinant of the thymoleptic effect. Lancet 1969; i: 132–6.CrossRefGoogle Scholar
5.Koyama, T, Meitzer, HY.A biochemical and neuroendocrine study of the serotonergic system in depression. In: Hippius, H, Klerman, GL, Matussek, N, red. New Results in Depression Research. Springer Verlag: Berlin, New York, 1986: 164–88.Google Scholar
6.Aprison, MH, Takahashi, R, Tachiki, K.Hypersensitive serotonergic receptors involved in clinical depression - a theory. In: Haber, B, Aprison, M, red. Neuropharmacology and Behavior. New York: Pergamon Press, 1977: 23–53.Google Scholar
7.Hoyer, D.The 5-HT receptor family: ligands, distribution and receptor-effector coupling. In: Rodgers, RJ, Cooper, SJ, red. 5-HT1A agonists, 5-HT3 antagonists and benzodiazepines: Their comparative behavioural pharmacology. Chichester: John Wiley & Sons, 1991: 31–47.Google Scholar
8.Wijngaarden, I van, Tulp, MThM, Soudijn, W.The concept of selectivity in 5-HT receptor research. Eur J Pharmacol 1990; 188:301–12.CrossRefGoogle ScholarPubMed
9.Willner, P.Behavioural models in psychopharmacology. In: Winner, P, red. Behavioural Models in Psychopharmacology. Cambridge: Cambridge Univ Press, 1991; 3–18.Google Scholar
10.Willner, P.Animal models of depression. In: Willner, P, red. Behavioural Models in Psychopharmacology. Cambridge: Cambridge Univ Press, 1991; 91–125.Google Scholar
11.Willner, P.The validity of animal models of depression. Psychopharmacol 1984; 83:1–6.CrossRefGoogle ScholarPubMed
12.Willner, P.Antidepressants and serotonergic neurotransmission: An integrative review. Psychopharmacol 1985; 85:387–404.CrossRefGoogle ScholarPubMed
13.Seiden, LS, Dahms, JL, Shaughnessy, RA.Behavioral screen for antidepressants: the effects of drugs and electroconvulsive shock on performance under differential-reinforcement-of-low-rate schedule. Psychopharmacol 1985; 86:55–60.CrossRefGoogle ScholarPubMed
14.Porsolt, RD, LePichon, M, Jaffre, M.Depression: a new animal model sensitive to antidepressant treatment. Nature 1977; 266:730–32.CrossRefGoogle Scholar
15.Borsini F, Meli.Is the forced swimming test a suitable model for revealing antidepressant activity? Psychopharmacol 1988; 94:147–60.CrossRefGoogle Scholar
16.Heyden, JAM van der, Olivier, B, Zethof, T.The behavioural despair model as a predictor of antidepressant activity: effects of serotonergic drugs. In: Olivier, B, Mos, J, Slangen, JL, red. Animal models in psychopharmacology. Basel: Birkhäuser Verlag, 1991; 211–15.CrossRefGoogle Scholar
17.Thiebot, MH, Martin, P.Effects of benzodiazepines, 5-HT1A agonists and 5-HT3 antagonists, in animal models sensitive to antidepressant drugs. In: Rodgers, RJ, Cooper, SJ, red. 5-HT1A agonists, 5-HT3 antagonists and benzodiazepines: their comparative behavioural pharmacology. Chichester: John Wiley & Sons, 1991; 159–94.Google Scholar
18.Porsolt, R, Lenègre, A, McArthur, RA.Pharmacological models of depression. In: Olivier, B, Mos, J, Slangen, JL, red. Animal Models, in Psychopharmacology. Basel: Birkhäuser Verlag, 1991; 137–59.CrossRefGoogle Scholar
19.Heyden, JAM van der, Molewijk, E, Olivier, B.Strain difference im response to drugs in the tail suspension test for antidepressant activity. Psychopharmacol 1987; 92:127–30.CrossRefGoogle Scholar
20.Hest, A van, Drimmelen, M van, Olivier, B.Flesinoxan shows antidepressant activity in a DRL72-S screen. Psychopharmacol 1992 (in press).Google Scholar
21.Marek, GJ, Li, AA, Seiden, LS.Evidence for involvement of 5-hydroxytryptamine1 receptors in antidepressant-like drug effects on differential-reinforcement-of-low-rate 72-second schedule. J Pharmacol exp Ther 1989; 250:60–71.Google Scholar
22.Pollard, GT, Howard, JL.Similar effects of antidepressant and non-antidepressant drugs on behavior under an interresponse-time >72-s schedule. Psychopharmacol 1986; 89:253–58.CrossRefGoogle ScholarPubMed
23.Marek, GJ, Li, AA, Seiden, LS.Selective 5-hydroxytryptamine2 antagonists have antidepressant-like effects on differential-reinfor-cement-of-low-rate 72-second schedule. J Pharmacol exp Ther 1989; 250: 52–9.Google ScholarPubMed
24.Danysz, W, Archer, T, Fowler, CJ.Screening for new antidepressant compounds. In: Willner, P, red. Behavioural Models in Psychopharmacology. Cambridge: Cambridge Univ Press, 1991; 126–56.Google Scholar
25.Amsterdam, JD, Berwish, N, Potter, L, Richels, K.Open trial of gepirone in the treatment of depressive disorder. Curr ther Res. 1987; 41:185–93.Google Scholar
26.Heller, AH, Beneke, M, Kuemme, B, Spencer, D, Kurtz, NM.Ipsapi-rone: evidence for efficacy in depression. Psychopharmacol Bull 1990; 26:219–23.Google ScholarPubMed
27.Rickeis, K, Amsterdam, J, Clary, C.Buspirone in depressed outpatients: a controlled study. Psychopharmacol Bull 1990; 26:163–69.Google Scholar
28.Johnson, AM.The comparative pharmacological properties of selective serotonin re-uptake inhibitors in animals. In: Feighner, JP,. Boyer, WF, red. Selective Serotonin Re-Uptake Inhibitors. Chichester: John Wiley & Sons, 1991; 37–70.Google Scholar
29.Schipper, J, Tulp, MThM, Berkelmans, B, Mos, J, Heyden, JAM vam der, Olivier, B.Preclinical pharmacology of flesinoxan: a potentiall anxiolytic and antidepressant drug. Hum Psychopharmacol 1991; 6: 553–61.CrossRefGoogle Scholar
30.Anseaux, M, Pitchot, W, Gonzalez-Moreno, Aet al.Pilot study of flesinoxan, a 5-HT1A agonist, in major depression. Biol Psychiat 1991; 29: 636S–37S.Google Scholar